Madrigal Pharmaceuticals announced ten data presentations at the upcoming European Association for the Study of the Liver, EASL, Congress, taking place from June 5-8, 2024 in Milan, Italy. “The data we will be presenting at EASL further support Rezdiffra as the foundational therapy in NASH and Madrigal as the leading company in the field,” said Bill Sibold, Chief Executive Officer of Madrigal. “We look forward to sharing multiple new data analyses from the MAESTRO Phase 3 program, including the first quality of life data, further analysis of noninvasive test results, and the first look at Rezdiffra in patients with metabolic dysfunction- and alcohol associated liver disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Paulson buys Carrols, exits SSR Mining in Q1
- 89bio price target lowered to $33 from $37 at Evercore ISI
- Akero Therapeutics price target lowered to $38 from $50 at Evercore ISI
- Madrigal Pharmaceuticals price target lowered to $200 from $270 at B. Riley
- Madrigal Pharmaceuticals management to meet with Oppenheimer